Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nicotine patch · 1 trial · 1 indication
Self-report of no smoking (not even a puff) during the previous 7 days, verified by expired carbon monoxide (CO; ≤5ppm), saliva cotinine (\<30 ng/mL), or significant other, and not invalidated by any of these verification measures. Failure to provide any of these 3 verification measures will result in PPA being considered missing.
| Arm | Type | Description |
|---|---|---|
| High-Intensity Aerobic Exercise | EXPERIMENTAL | Participants assigned to this arm will be instructed to complete 75 minutes per week of aerobic training at 60-85% of the their heart rate reserve. |
| Low-Intensity Aerobic Exercise | ACTIVE_COMPARATOR | Participants assigned to this arm will be instructed to complete 75 minutes per week of aerobic training at 20-40% of the their heart rate reserve. |
| Name | Type | Description |
|---|---|---|
| Aerobic Exercise | BEHAVIORAL | Participants will select a YMCA branch and will be assigned a personal fitness instructor who will oversee a 15-week exercise intervention. The weekly exercise prescription is 75 minutes of aerobic training. |
| Counseling | BEHAVIORAL | Participants will receive the standard tobacco cessation package of up to 5 proactive interactions from the Texas Tobacco Quitline (TTQ). Interactions are typically phone calls, but can be chat or live text if the participant prefers. Interaction 1 is for assessment and quit date planning, Interaction 2 occurs prior to the quit date and can be a group session, Interaction 3 occurs shortly following the quit date, and Interactions 4 and 5 are for relapse prevention if the smoker has quit or problem solving if they have not quit. TTQ also offers a tobacco cessation text messaging program and access to a web portal with a variety of cessation resources. |
| Nicotine patch | DRUG | On the target quit day (week 6), participants will be provided 8 weeks of nicotine replacement therapy (24-hour transdermal nicotine patches \[TNP\]). |
Inclusion Criteria: * Adult (age ≥ 18); * High Anxiety Sensitivity (≥5 on the Short Scale Anxiety Sensitivity Index \[SSASI\]); * Daily smoker, ≥5 cigarettes (including e-cigarettes, little cigars/cigarillos) for ≥1 year; * Motivated to quit smoking as evidenced by a score of ≥5 on a 0-10 Likert sc...
Nicotine patch is used for nicotine dependence, specifically as part of a community-based smoking cessation treatment for adults with high stress sensitivity. It is being studied in a Phase 3 clinical trial to help individuals quit smoking by reducing nicotine withdrawal symptoms and cravings.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is developing the Nicotine patch. The company is conducting a Phase 3 clinical trial to evaluate its effectiveness in treating nicotine dependence in adults with high stress sensitivity.
Nicotine patch is currently in Phase 3 clinical development. It is an investigational product being studied for nicotine dependence, and it has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is actively recruiting participants.
Nicotine patch is being evaluated in a Phase 3 clinical trial with the identifier NCT06053567. This study, titled 'Community-based Smoking Cessation Treatment for Adults With High Stress Sensitivity,' is recruiting 360 participants in the United States and is actively enrolling.
Nicotine patch is a form of nicotine replacement therapy, but it is specifically being developed by Jasper Therapeutics for smoking cessation in adults with high stress sensitivity. The trial uses an active-controlled design, meaning it is compared against another active treatment.